Abstract��Chondroitin sulfate (CS) is a heterogeneous and negatively charged polysaccharide composed of repeating disaccharideunits, and has many pharmacological activities. CS has been recommended as symptomatic slow acting drugs for osteoarthritis (SYSADOA) in clinical practice. CS is shown to have promising prospect as a potential candidate for anti-metastasis of cancers and as a neurite outgrowth agent for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease characterized by progressive loss of neurons.Moreover, CS is also involved in interaction with virus during its cell entry, wound healing and osteogenesis, and may be a promising drug candidate in these areas. Based on original publications, the research advances of CS in these areas and its applications were reviewed.The possibility of chemoenzymatic synthesis of specific CS chains as potential drugs was also discussed here, which may be used in the treatment of osteoarthritis, anti-metastasis of cancers, and so on.
ROGERS C J,CLARK P M,TULLY S E, et al. Elucidating glycosaminoglycan-protein-protein interactions using carbohydrate microarray and computational approaches[J]. Proc Natl Acad Sci USA, 2011, 108(24):9747-9752.
[2]
KOBAYASHI T, YAN H, KURAHASHI Y, et al. Role of galNAc4S-6ST in astrocytic tumor progression[J]. PLoS One, 2013, 8(1):e54278.
[3]
ZHOU Y G. Chondroitin sulfate in the preparation of glycosaminoglycan from mackerel (Pneumatophorus japonicas Houttuyn) nasal cartilage and its interaction with growth factors[J]. J Agri Biotech(ũҵ���＼��ѧ��), 2012,20(1):48-53.
[4]
DU SOUICH P. Absorption, distribution and mechanism of action of SYSADOAS[J]. Pharmacol Ther,2014, 142(3):362-374.
[5]
MARTEL-PELLETIER J, FARRAN A, MONTELL E, et al. Discrepancies in composition and biological effects of different formulations of chondroitin sulfate[J]. Molecules, 2015, 20(3):4277-4289.
[6]
LI F, TEN DAM G B, MURUGAN S, et al. Involvement of highly sulfated chondroitin sulfate in the metastasis of the Lewis lung carcinoma cells[J]. J Biol Chem, 2008, 283(49):34294-34304.
[7]
BASAPPA, RANGAPPA K S, SUGAHARA K. Roles of glycosaminoglycans and glycanmimetics in tumor progression and metastasis[J]. Glycocoj J, 2014, 31(6-7):461-467.
[8]
PURUSHOTHAMAN A,FUKUDA J,MIZUMOTO S, et al. Functions of chondroitin sulfate/dermatan sulfate chains in brain development. Critical roles of E and iE disaccharide units recognized by a single chain antibody GD3G7[J]. J Biol Chem, 2007, 282(27):19442-19452.
[9]
PULSIPHER A, GRIFFIN M E, STONE S E, et al. Directing neuronal signaling through cell-surface glycan engineering[J]. J Am Chem Soc, 2014, 136(19):6794-6797.
[10]
CALAMIA V, FERN��NDEZ-PUENTE P, MATEOS J, et al. Pharmacoproteomic study of three different chondroitin sulfate compounds on intracellular and extracellular human chondrocyte proteomes[J]. Mol Cell Proteomics, 2012, 11(6):M111.013417.
[11]
WILDI L M, RAYNAULD J P, MARTEL-PELLETIER J, et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy:a randomised, double-blind, placebo-controlled pilot study using MRI[J]. Ann Rheum Dis, 2011,70(6):982-989.
[12]
M?LLER I, P��REZ M, MONFORT J, et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis:a randomized, double-blind, placebo-controlled study[J]. Osteoarthr Cartil, 2010, 18(suppl 1):32-40.
[13]
HOCHBERG M C, MARTEL-PELLETIER J, MONFORT J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis:a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib[J]. Ann Rheum Dis, 2015, 75(1):37-44.
[14]
JINNO-OUE A, TANAKA A, SHIMIZU N, et al. Inhibitory effect of chondroitin sulfate type E on the binding step of human T-cell leukemia virus type 1[J]. AIDS Res Hum Retrov, 2013, 29(3):621-629.
[15]
ZOU X H, JIANG Y Z, ZHANG G R, et al. Specific interactions between human fibroblasts and particular chondroitin sulfate molecules for wound healing[J]. Acta Biomater, 2009, 5(5):1588-1595.
[16]
KOIKE T, IZUMIKAWA T, TAMURA J, et al. Chondroitin sulfate-E fine-tunes osteoblast differentiation via ERK1/2, Smad3 and Smad1/5/8 signaling by binding to N-cadherin and cadherin-11[J]. Biochem Biophys Res Commun, 2012, 420(3):523-529.
[17]
MIZUMOTO S, TAKAHASHI J, SUGAHARA K. Receptor for advanced glycation end products (RAGE) functions as receptor for specific sulfated glycosaminoglycans, and anti-RAGE antibody or sulfated glycosaminoglycans delivered in vivo inhibit pulmonary metastasis of tumor cells[J]. J Biol Chem, 2012, 287(23):18985-18994.
[18]
FUSTER M M, ESKO J D. The sweet and sour of cancer:glycans as novel therapeutic targets[J]. Nat Rev Cancer, 2005, 5(7):526-542.
[19]
GARC��A-AL��AS G, BARKHUYSEN S, BUCKLE M, et al. Chondroitinase ABC treatment opens a window of opportunity for task-specific rehabilitation[J]. Nat Neurosci,2009, 12(9):1145-1151.
[20]
DE VIVO L, LANDI S, PANNIELLO M, et al. Extracellular matrix inhibits structural and functional plasticity of dendritic spines in the adult visual cortex[J]. Nat Commun, 2013, 4:1484.
[21]
MIKAMI T, YASUNAGA D, KITAGAWA H. Contactin-1 is a functional receptor for neuroregulatory chondroitin sulfate-E[J]. J Biol Chem, 2009, 284(7):4494-4499.
[22]
LIU P, CHEN L, TOH J K C, et al. Tailored chondroitin sulfate glycomimetics via a tunable multivalent scaffold for potentiating NGF/TrkA-induced neurogenesis[J]. Chem Sci, 2015, 6(1):450-456.
[23]
BEURDELEY M, SPATAZZA J, LEE H H C, et al. Otx2 binding to perineuronal nets persistently regulates plasticity in the mature visual cortex[J]. J Neurosci, 2012, 32(27):9429-9437.
[24]
CIMINI D, DE ROSA M, CARLINO E, et al. Homologous overexpression of RfaH in E. coli K4 improves the production of chondroitin-like capsular polysaccharide[J]. Microb Cell Fact, 2013, 12(1):46.
[25]
HE W, FU L, LI G, et al. Production of chondroitin in metabolically engineered E. coli[J]. Metab Eng, 2015, 27(1):92-100.
[26]
WANDEL S, JUNI P, TENDAL B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee:network Meta-analysis[J]. BMJ, 2010, 341:c4675.
[27]
GABAY C, MEDINGER-SADOWSKI C, GASCON D, et al. Symptomatic effects of chon-droitin 4 and chondroitin 6 sulfate on hand osteoarthritis:a randomized,double-blind, placebo-controlled clinical trial at a single center[J]. Arthritis Rheum, 2011, 63(11):3383-3391.
[28]
ZEGELS B, CROZES P, UEBELHART D, et al. Equivalence of a single dose (1 200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate inpatients with knee osteoarthritis. Results of a randomized double blind placebocontrolled study[J]. Osteoarthr Cartil, 2013, 21(1):22-27.
[29]
HOCHBERG M C, ZHAN M, LANGENBERG P. The rate of decline of joint space width inpatients with osteoarthritis of the knee:a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate[J]. Curr Med Res Opin, 2008, 24(11):3029-3035.
[30]
HOCHBERG M. Structure-modifying effects of chondroitin sulfate in kneeosteoarthritis:an updated meta-analysis of randomized placebo-controlledtrials of 2-year duration[J]. Osteoarthr Cartil, 2010, 18(suppl 1):28-31.
[31]
LEE Y H, WOO J H, CHOI S J, et al. Effect of glucosamine or chondroitin sulfate on theosteoarthritis progression:a Meta-analysis[J]. Rheumatol Int, 2010, 30(3):357-363.
[32]
ZHOU Y G. Chemoenzymatic synthesis of heparan sulfate/heparin:research advances[J]. J Int Pharm Res(����ҩѧ�о���־), 2014, 41(6):630-636.
[33]
CAI C, SOLAKYILDIRIM K, YANG B, et al. Semi-synthesis of chondroitinsulfate-E from chondroitinsulfate-A[J]. Carbohydr Polym, 2012, 87(1):822-829.
2016, Vol. 51 
